2018 Press Releases

2018 Press Releases
Home / 2018 Press Releases

2018 Press Releases

Mar-19-2018

Protalix BioTherapeutics Announces Acceptance of Abstract on OPRX-106 as a Lecture Presentation at the Digestive Diseases Week® 2018

CARMIEL, Israel, March 19, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that an abstract detailing the results from the Company’s phase IIa clinical trial of OPRX-106 for the treatment of ulcerative colitis results has been accepted for a lectu... 
Mar-15-2018

Protalix BioTherapeutics to Present at BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference

CARMIEL, Israel, March 15, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that Moshe Manor, the Company's President and Chief Executive Officer, will present a corporate overview at BioCentury’s 25th Annual Future Leaders in the Biotech Industry ... 
Mar-13-2018

Protalix BioTherapeutics Announces Positive Results from Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis

Clinical Responses Observed in 67% of Patients and Clinical Remission Observed in 28% of Patients No Anti-Drug Antibodies Detected CARMIEL, Israel, March 13, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), announced today, positive results from the Company’s phase II clinical trial of OPRX-106 for the treatment of ulcerative colitis.  OPRX-106 is a plant cell-expressed recombinant human tumor necrosis factor receptor II fused to an IgG1 Fc domain (TN... 
Mar-06-2018

Protalix BioTherapeutics Reports 2017 Full Year Results and Provides Corporate Update

Enrollment in all Fabry Trials is ongoing in over Forty Active Sites Current Cash is Projected to Fund the Company through Clinical Trial Read-Outs and into 2020 CARMIEL, Israel, March 06, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announce... 
Feb-26-2018

Protalix BioTherapeutics to Hold Full-Year 2017 Financial Results and Corporate Update Conference Call on March 6, 2018

CARMIEL, Israel, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it will report full-year 2017 financial results and provide a corporate update on Tuesday, March 6, 2018 at 8:30 am ET. To participate in the conference call, please... 
Feb-15-2018

Protalix BioTherapeutics Announces Final Dosing of Last Patient in Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis

CARMIEL, Israel, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), announced today the final dosing of the last patient in the Company’s phase II clinical trial evaluating OPRX-106, the Company’s oral antiTNF product candidate, in patients with ulcerative colitis (UC).  OPRX-106 is the Company’s proprietary plant cell-expressed recombinant human tumor necrosis factor receptor II fused to an IgG1 Fc domain (TNFRII-Fc).  The Company expects to repor... 
Jan-31-2018

Protalix BioTherapeutics’ pegunigalsidase alfa Receives Fast Track Designation from the U.S. Food and Drug Administration

Fast Track designation highlights high unmet medical need in the treatment of Fabry disease CARMIEL, Israel, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pegunigalsidase alfa, or PRX-102, the Company’s plant cell-expressed recombinant, pegylated, cross-linked α-galactosidase-A candidate for the treatment of Fabry disease.  The FDA’s Fast Track ... 
Jan-29-2018

Protalix BioTherapeutics to Participate in the 14th Annual WORLDSymposium™ 2018

Data to be presented in an oral presentation and two poster presentations CARMIEL, Israel, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the Company will participate in the 14th Annual WORLDSymposium™ 2018 taking place February 5 – 8, 2018 at the Manchester Grand Hyatt, San Diego, CA. Presentations Details: “Enhanced pharmacokinetics profile of pegunigalsidase alfa (PRX-102) supports once-monthly 2mg/kg dosing for the ... 
Jan-02-2018

Protalix BioTherapeutics Reports Positive Interim Data from Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis

CARMIEL, Israel, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), announced today interim data from the first 14 patients that completed, to date, the Company’s phase II clinical trial of OPRX-106 (oral anti-TNF) in patients with ulcerative colitis. The phase II clinical trial is a randomized, open label, 2-arm study of OPRX-106 in patients with active mild to moderate ulcerative colitis.  A total of 24 patients were enrolled and randomized to...